Cargando…

No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project

BACKGROUND: We compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. METHODS: Beginning in May 2003, participants with CD4 cell counts <250 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Okoboi, Stephen, Ekwaru, Paul John, Campbell, James D., Egessa, Aggrey, King, Racheal, Bakanda, Celestin, Muramuzi, Emmy, Kaharuza, Frank, Malamba, Samuel, Moore, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736157/
https://www.ncbi.nlm.nih.gov/pubmed/26830678
http://dx.doi.org/10.1186/s12889-016-2781-y
_version_ 1782413221412470784
author Okoboi, Stephen
Ekwaru, Paul John
Campbell, James D.
Egessa, Aggrey
King, Racheal
Bakanda, Celestin
Muramuzi, Emmy
Kaharuza, Frank
Malamba, Samuel
Moore, David M.
author_facet Okoboi, Stephen
Ekwaru, Paul John
Campbell, James D.
Egessa, Aggrey
King, Racheal
Bakanda, Celestin
Muramuzi, Emmy
Kaharuza, Frank
Malamba, Samuel
Moore, David M.
author_sort Okoboi, Stephen
collection PubMed
description BACKGROUND: We compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. METHODS: Beginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2009. We used Cox Proportional Hazard models to determine if study arm was independently associated with the development of opportunistic infections (OIs) or death. RESULTS: We randomized 1211 participants to the three original study arms and 331 surviving participants in the clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. At enrolment the median age was 38 years and the median CD4 cell count was 134 cells/μL. Over a median of 5.2 years of follow-up, 37 deaths and 35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. We did not observe an association between monitoring arm and new OIs or death (AHR =1.19 for CD4-only vs. CD4-VL; 95 % CI 0.82–1.73). CONCLUSION: We found no differences in clinical outcomes associated with the addition of quarterly VL monitoring to quarterly CD4 cell count monitoring.
format Online
Article
Text
id pubmed-4736157
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47361572016-02-03 No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project Okoboi, Stephen Ekwaru, Paul John Campbell, James D. Egessa, Aggrey King, Racheal Bakanda, Celestin Muramuzi, Emmy Kaharuza, Frank Malamba, Samuel Moore, David M. BMC Public Health Research Article BACKGROUND: We compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. METHODS: Beginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2009. We used Cox Proportional Hazard models to determine if study arm was independently associated with the development of opportunistic infections (OIs) or death. RESULTS: We randomized 1211 participants to the three original study arms and 331 surviving participants in the clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. At enrolment the median age was 38 years and the median CD4 cell count was 134 cells/μL. Over a median of 5.2 years of follow-up, 37 deaths and 35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. We did not observe an association between monitoring arm and new OIs or death (AHR =1.19 for CD4-only vs. CD4-VL; 95 % CI 0.82–1.73). CONCLUSION: We found no differences in clinical outcomes associated with the addition of quarterly VL monitoring to quarterly CD4 cell count monitoring. BioMed Central 2016-02-01 /pmc/articles/PMC4736157/ /pubmed/26830678 http://dx.doi.org/10.1186/s12889-016-2781-y Text en © Okoboi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Okoboi, Stephen
Ekwaru, Paul John
Campbell, James D.
Egessa, Aggrey
King, Racheal
Bakanda, Celestin
Muramuzi, Emmy
Kaharuza, Frank
Malamba, Samuel
Moore, David M.
No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title_full No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title_fullStr No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title_full_unstemmed No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title_short No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
title_sort no differences in clinical outcomes with the addition of viral load testing to cd4 cell count monitoring among hiv infected participants receiving art in rural uganda: long-term results from the home based aids care project
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736157/
https://www.ncbi.nlm.nih.gov/pubmed/26830678
http://dx.doi.org/10.1186/s12889-016-2781-y
work_keys_str_mv AT okoboistephen nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT ekwarupauljohn nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT campbelljamesd nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT egessaaggrey nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT kingracheal nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT bakandacelestin nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT muramuziemmy nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT kaharuzafrank nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT malambasamuel nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject
AT mooredavidm nodifferencesinclinicaloutcomeswiththeadditionofviralloadtestingtocd4cellcountmonitoringamonghivinfectedparticipantsreceivingartinruralugandalongtermresultsfromthehomebasedaidscareproject